<DOC>
	<DOCNO>NCT02355782</DOCNO>
	<brief_summary>The purpose compassionate use study , two patient thrombotic microangiopathy , provide expand access patient participate clinical trial OMS721-TMA-001 improvement disease marker observe treatment patient could otherwise benefit treatment . This treatment protocol ; research protocol.Therefore , patient study OMS721-TMA-001 deem eligible investigator may participate .</brief_summary>
	<brief_title>OMS721 Compassionate Use Patients With Thrombotic Microangiopathy</brief_title>
	<detailed_description>The study open-label , expand access study provide continue OMS721 treatment compassionate use patient participate clinical trial OMS721-TMA-001 . Patients eligible marker disease activity , platelet count , LDH , haptoglobin , observe improve study patient disease activity remain stable , could treat high dose may beneficial . Safety measure adverse event laboratory measure monitor . Markers disease activity , pharmacokinetics ex vivo pharmacodynamics also monitor .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Thrombotic Microangiopathies</mesh_term>
	<criteria>Have diagnosis thrombotic microangiopathy relate aHUS , TTP stem cell transplant . Have complete treatment clinical trial OMS721TMA001 . Investigator determine continued treatment OMS721 could beneficial . Aged 18 year old . Hypersensitivity OMS721 excipients . Have serious medical condition increase risk OMS721 treatment patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>TMA , aHUS , TTP , stem cell transplant-associated TMA</keyword>
</DOC>